Treviamet 50mg/1000mg

Indication

Treviamet (Sitagliptin 50 mg + Metformin HCl 1000 mg) is a fixed-dose combination antidiabetic used as adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor and metformin is a biguanide; together they provide complementary mechanisms of action.

Ingredients

• Sitagliptin
• Metformin HCl

Direction

Adults: 1 tablet (Sitagliptin 50 mg/Metformin 1000 mg) twice daily with meals to reduce gastrointestinal side effects. Dose is individualised by a physician based on current therapy and renal function.

Side effects

• Nausea
• diarrhea
• abdominal pain (metformin)
• Nasopharyngitis
• upper respiratory tract infection (sitagliptin)
• Headache
• Hypoglycaemia (especially when combined with sulfonylureas or insulin)
• Lactic acidosis (rare but serious — metformin)
• Pancreatitis (rare)

Precautions

• Contraindicated in patients with eGFR < 30 mL/min/1.73 m² (severe renal impairment).
• Withhold before and 48 hours after iodinated contrast media administration.
• Risk of lactic acidosis from metformin component in renal
• hepatic impairment
• or with excessive alcohol.
• May cause pancreatitis
• discontinue if severe abdominal pain occurs.
• Not for use in type 1 diabetes or diabetic ketoacidosis.
• Use with caution in the elderly
• monitor renal function regularly.
• Keep out of reach of children.